- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FILAMENT HEALTH Aktie jetzt für 0€ handeln | |||||
| 09.05. | Filament Health reports Q1 results | 1 | Seeking Alpha | ||
| 09.05. | Filament Health Announces First Quarter 2025 Financial Results And Operational Highlights | 3 | CNW | ||
| 09.04. | Filament Health Corp: Filament receives U.S. FDA OK for PEX010 study | 1 | Stockwatch | ||
| 09.04. | Filament Health Announces Fda Authorization Of Phase 2 Clinical Trial Studying Pex010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder | 2 | CNW | ||
| 04.04. | Filament Health to raise C$0.9M, delist from Cboe Canada | 1 | Seeking Alpha | ||
| 04.04. | Filament Health Corp: Filament Health arranges $900,000 private placement | 2 | Stockwatch | ||
| 04.04. | Filament Health Corp.: Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada | 113 | PR Newswire | Financing driven by existing investor Negev and Filament's Board of Directors
Company also announces intention to voluntarily delist from Cboe Canada
VANCOUVER... ► Artikel lesen | |
| 01.04. | Filament Health Corp.: Filament Health Reports Q4 And Year End 2024 Financial Results And Operational Highlights | 69 | PR Newswire | VANCOUVER, BC, April 1, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 01.04. | Filament Health reports FY results | 1 | Seeking Alpha | ||
| 17.03. | Filament Health Corp: Filament Health talks PEX010 safety data | 1 | Stockwatch | ||
| 17.03. | Filament Health Corp.: Filament Health Announces Positive Data From Phase 2 Study Of Pex010 In Patients With Alcohol Use Disorder | 57 | PR Newswire | Open-label study at Psychiatric Centre Copenhagen found that alcohol consumption significantly decreased amongst participants dosed with Filament's botanical psilocybin... ► Artikel lesen | |
| 06.02. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference | 432 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as... ► Artikel lesen | |
| 22.01. | Filament Health Corp: Filament Health ships PEX010 to UW-Madison | 1 | Stockwatch | ||
| 21.01. | Filament Health Announces Shipment Of Botanical Psilocybin To The University Of Wisconsin-madison | 1 | CNW | ||
| 07.01. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum | 440 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications... ► Artikel lesen | |
| 16.12.24 | Filament Health Corp: Filament Health JV Magdalena imports six kg coca leaf | 2 | Stockwatch | ||
| 16.12.24 | Filament Health Announces Import Of Coca Leaf From Peru By Joint Venture Magdalena Biosciences | 3 | CNW | ||
| 15.11.24 | Filament Health Corp.: Filament Health Announces Third Quarter 2024 Financial Results And Operational Highlights | 57 | PR Newswire | VANCOUVER, BC, Nov. 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 10.10.24 | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum | 596 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications... ► Artikel lesen | |
| 15.06.24 | Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp. | 704 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the "Acquiror"), a shareholder of Filament Health Corp. ("Filament"), announces that on June 12, 2024,... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 22,865 | +3,13 % | Bayer-Aktie: Kurs klettert leicht (23,995 €) | An der deutschen Börse liegt das Wertpapier von Bayer aktuell im Plus. Die Aktie notiert gegenwärtig bei 24,00 Euro. Am Aktienmarkt liegt die Aktie von Bayer zur Stunde im Plus. Das Wertpapier legte... ► Artikel lesen | |
| AURORA CANNABIS | 4,455 | +0,56 % | BRISANTE Meldung setzt Aurora Cannabis Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| CANOPY GROWTH | 1,202 | +0,84 % | Starke Zahlen, Aktie steigt: Nicht Canopy Growth: Diese Cannabis-Aktie gibt es jetzt umsonst! | © Foto: Dall-EDas Cannabisunternehmen Cronos hat am Donnerstagmittag starke Quartalszahlen vorgelegt - und im Unterschied zu Canopy Growth einen Nettogewinn erzielt.Innerhalb der Cannabis-Branche gilt... ► Artikel lesen | |
| TILRAY BRANDS | 0,397 | +1,02 % | Tilray Brands Inc: Tilray's High Park roll outs XMG Atomic Sours line | ||
| INNOCAN PHARMA | 0,108 | +3,37 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| CRONOS GROUP | 1,850 | -0,80 % | Cronos Group Inc.: Cronos Group Reports 2025 First Quarter Results | Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS® retained its position as the number one cannabis brand in... ► Artikel lesen | |
| SYNBIOTIC | 3,155 | -0,32 % | EQS-DD: SYNBIOTIC SE: HempConsult GmbH, Verleih (unentgeltlich) von 50.000 Aktien im Rahmen einer Wertpapierleihe. | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
23.04.2025 / 09:22... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 4,884 | -4,52 % | Green Thumb Industries should be a core holding for cannabis investors, analyst says | ||
| CHRISTINA LAKE CANNABIS | 0,025 | 0,00 % | Christina Lake Cannabis Corp.: Christina Lake Cannabis Announces Financing | VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the "Company" or "CLC" or "Christina Lake Cannabis") (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) the Company... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 92,84 | -3,21 % | Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone | WASHINGTON (dpa-AFX) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced that it has entered into a $570 million term loan and revolving credit facility with funds managed... ► Artikel lesen | |
| JAGUAR HEALTH | 5,460 | -11,51 % | Jaguar Health, Inc.: Jaguar Health Reports First Quarter 2025 Financials | The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 95,44 | +0,59 % | Major Purchase Alert: Seamus Mulligan Invests $9.99M In Jazz Pharmaceuticals Stock | ||
| TRULIEVE CANNABIS | 4,346 | +4,22 % | Trulieve Cannabis Corp: Trulieve opens Lorain, Ohio, dispensary | ||
| JUVA LIFE | 0,023 | -100,00 % | Juva Life Inc. Updates Shareholders on Court-Appointed Receivership Proceedings | REDWOOD CITY, CA / ACCESSWIRE / November 25, 2024 / Juva Life Inc. (CSE:JUVA)(OTC PINK:JUVAF)(FRANKFURT:4VV) ("Juva" or the "Company"), a life science company with both pharmaceutical research and development... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,400 | 0,00 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen |
Das Unternehmen FILAMENT HEALTH CORP kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FILAMENT HEALTH CORP finden Sie auf Wallstreet Online.